We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Grants Tentative Approval to Merck’s Insulin Glargine Copycat
FDA Grants Tentative Approval to Merck’s Insulin Glargine Copycat
The FDA granted tentative approval for Merck’s Lusduna Nexvue (insulin glargine injection), as a follow-on basal insulin biologic, a product similar to Sanofi’s flagship Lantus treatment.